MedPath

The verification study for long-term intake safety and the effect on skin barrier function (moisturizing power) of test food intake; A randomized, placebo-controlled, double-blind, parallel study

Not Applicable
Conditions
Healthy subjects
Registration Number
JPRN-UMIN000050422
Lead Sponsor
Pharma Foods International Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. Subjects who have serious current or past diseases such as brain disease, malignant tumor, immune disease, diabetes, renal disease, heart disease, thyroid disease, adrenal disease, and other metabolic diseases 2. Currently undergoing treatment for any of the following chronic diseases: arrhythmia, dyslipidemia, hypertension, and other chronic diseases 3. Subjects with severe skin disease symptoms such as atopy or dermatitis 4. Subjects who cannot intentionally refrain from exposure to direct sunlight, such as sunburn 5. Subjects who are allergic to medications and/or the test food related products 6. Subjects who are pregnant, breast-feeding, or planning to become pregnant 7. Currently, or within the past 2 weeks, subjects who have a habit of continuously taking drugs (pharmaceuticals and quasi-drugs with moisturizing effects, anti-wrinkle effects, etc.) or health foods that claim to have skin-improving effects, or subjects who have a habit of applying the above drugs on their arms 8. Subjects who are judged to be unsuitable as subjects based on clinical test values and skin test values at the time of screening 9. Subjects who are judged as ineligible to participate in the study by the physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
(Effectiveness evaluation) 1. Transepidermal Water Loss (TEWL) * Assess these tests at screening (before consumption) and at 4, 8 and 12 weeks after consumption.
Secondary Outcome Measures
NameTimeMethod
(Safety evaluation) 1.Physical measurement 2.Vital signs(Blood pressure/pulse) 3.Blood biochemistry 4.Blood hematology 5.Urinalysis 6.Adverse events * Assess these tests at screening (before consumption) and at 4, 8 and 12 weeks after consumption and 4 weeks after consumption completed. (Effectiveness evaluation) 1.Moisture of the skin surface 2.Visual Analogue Scale (VAS) of itching sensation 3.The Japanese version of Skindex-29 * Assess these tests at screening (before consumption) and at 4, 8 and 12 weeks after consumption.
© Copyright 2025. All Rights Reserved by MedPath